Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulatory therapy for psychiatric disorders with dysimmunity (Phase III)
2021-005078-25Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in Mental and behavioural disorders with immune dysregulation (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Remission of psychiatric symptoms at 3 months. Started Jun 2022; status: active.
02
Drugs
rituximab
03
Conditions
Mental and behavioural disorders with immune dysregulation
Beyond the preview
Go deeper on 2021-005078-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005078-25.